Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03075072 : Whole Brain Radiation Versus Stereotactic Radiation (SRS) in Patients With 5-20 Brain Metastases: A Phase III, Randomized Clinical Trial
PhasePhase 3
AgesMin: 18 Years Max: 80 Years
Inclusion Criteria:

- Participants must have a biopsy proven solid malignancy with untreated (by radiation)
intracranial lesions radiographically consistent with or pathologically proven to be
brain metastases. Patients who have undergone prior systemic therapy are eligible

- Five-fifteen intracranial lesions must be present on MRI of the brain

- Age 18-80 years at diagnosis of brain metastases

- Karnofsky performance status of at least 70

Exclusion Criteria:

- Participants who have undergone prior radiation for brain metastases.

- Patients who have undergone resection of one or more brain metastases but who have not
yet started adjuvant radiotherapy are eligible for the study

- Participants who cannot undergo a brain MRI

- Participants who cannot receive gadolinium (MRI contrast)

- Participants with stage IV-V chronic kidney disease or end stage renal disease

- Participants with widespread, definitive leptomeningeal disease

- Participants with small cell lung cancer, lymphoma, or myeloma

- Participants with a maximum tumor diameter exceeding 5 cm (if not resected)
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557